Peptide having an extending action for half-life of object peptide in plasma

a technology of object peptide and peptide, which is applied in the field of peptide having an extending action for the half-life of object peptide in plasma, can solve the problems of long time and cost that are necessary for actual application, and achieve excellent safety, improved pharmacokinetics in vivo, and reduced cost and time

Active Publication Date: 2010-12-02
DAIICHI SANKYO CO LTD
View PDF4 Cites 42 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0212]When the peptide where half-life is extended according to the present invention is added to an object peptide having a short half-life, the pharmacokinetics in vivo are improved and a product having a half-life which is practical as a drug is achieved. Since its antigenic property is almost the same as those of the object peptide of a native, it has an excellent safety and shows resistance to enzymes which decompose a physiologically active peptide in vivo. When the peptide where the half-life is extended is used, it is now possible to greatly reduce the cost and time which have been necessary for the development of physiologically active peptides where the pharmacokinetics in vivo are improved. In addition, it is possible that an administering method for the physiologically active peptide used for the treatment by a continuous intravenous administration or a continuous subcutaneous administration is conducted in a single-time bolus administration whereby it is now expected to improve the compliance of the individual (patient) and of a medical field.

Problems solved by technology

Therefore, much time and cost for a long period of time are necessary for actual application.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peptide having an extending action for half-life of object peptide in plasma
  • Peptide having an extending action for half-life of object peptide in plasma
  • Peptide having an extending action for half-life of object peptide in plasma

Examples

Experimental program
Comparison scheme
Effect test

example 1

Changes in ANP Concentration of Native ANP or Chimeric ANP in Plasma

[0323]Changes in ANP immunoreactivity concentration in plasma when a native ANP and a chimeric peptide (chimeric ANP) to which a half-life-extension peptide was bestowed were administered into vein of rats were investigated.

[0324]The experiment was conducted using rats into which polyethylene tube (PE-50; manufactured by Clay Adams) was previously inserted into thigh artery under an anesthetized condition with Nembutal. As a test system, male rats of an SD strain of 7 weeks age (provided from Nippon Charles River) were subjected to the experiment where one group comprised three rats. Native ANP (α-hANP, SEQ ID No; 100) or a chimeric ANP (A, B and C) each was administered to the rat intravenously or subcutaneously (back) in a dose of 0.1 mg / kg and blood over the time from before the administration until 90 or 180 minutes after the administration was collected by a polyethylene tube inserted into thigh artery. A stabi...

example 2

Concentration Changes in Plasma and Biological Activity of Native CNP-22 and Chimeric CNP

[0331]Changes in CNP immunoreactivity concentration in plasma of native CNP-22 and chimeric peptide (chimeric CNP) where a half-life-extension peptide was added to CNP were investigated.

[0332]The experiment was conducted in the same manner as in Example 1 that rats where polyethylene tube was previously inserted into thigh artery were used under an anesthetizing condition with Nembutal and male SD strain rats of 7 weeks age (purchased from Nippon Charles River) were used where one group comprised 3 rats. Native CNP-22 (SEQ ID No: 101) or a chimeric CNP (A and B) each was administered to the rat intravenously (tail) or subcutaneously (back) in a dose of 0.1 mg / kg and the blood over the time from before the administration until 90 or 180 minutes after the administration was collected by a polyethylene tube inserted into thigh artery. EDTA (manufactured by Dojin Laboratories) and aprotinin (manufac...

example 3

Resistance of Native CNP-22 and Chimeric CNP to Peptidase

[0340]Resistance of native CNP-22 and chimeric CNP to peptidase was investigated.

[0341]The experiment was conducted in N=2 for each sample. Native CNP-22, chimeric CNP (A, B) (structure mentioned already; final concentration: 0.5 μg / mL) and 100 μL of reaction solution (medium: 20 mM MES, pH 6.5) of human type recombinant neutral endopeptidase (hNEP, manufactured by R&D Systems, Inc., U.S.A.) were prepared. The initial value sample was boiled for 5 minutes immediately after preparation. Sample for the stability evaluation was subjected to an enzymatic reaction in a constant-temperature vessel set at 37° C. for 1 hour and then boiled for 5 minutes. Distilled water (100 μL) was added to the sample after boiling followed by well mixing and 50 μL thereof was analyzed in a water-acetonitrile system using a high-performance liquid chromatography system LC-10A (manufactured by Shimadzu). The analytical data were analyzed by a Chromato...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
acidic amino acidaaaaaaaaaa
pharmaceutical compositionaaaaaaaaaa
timeaaaaaaaaaa
Login to view more

Abstract

A peptide of the following (I) or (II).
    • (I) a peptide represented by the formula B, A-B, B-C or A-B-C in which A, B and C each is represented by the following (1), (2) and (3) and, when it is bonded to other object peptide, it is able to extent the half-life in plasma as compared with the object peptide where the physiological activity of the object peptide is still retained.
    • (II) a peptide comprising a reversed sequence of the peptide of (I); a sequence which is represented by A-B in (I) and A or B is reversed; a sequence which is represented by B-C in (I) and B or C is reversed; or a sequence which is represented by A-B-C in (I) and A, B, C, A and B, B and C or A and C is reserved.
    • (1) A is a peptide comprising 1 to 14 of any amino acid(s)
    • (2) B is a peptide represented by the formula 1:
(Wk-Xl-Y-Zm-Wn)-(Wo-Xp-Y-Zq-Wr)s
    • (In the formula 1, W is a basic amino acid; X and Z are any amino acids; Y is an acidic amino acid; k is 1 or 2; l is an integer of 4≧l≧0; m is an integer of 2≧m≧0; 4≧l+m≧0; n is 1 or 2; o is 1 or 2; p is an integer of 4≧p≧0; q is an integer of 2≧q≧0; 4≧p+q≧0; r is 1 or 2; and s is 0 or 1.)
    • (3) C is a peptide comprising 2 to 14 of any amino acids.

Description

TECHNICAL FIELD[0001]The present invention relates to a peptide which is able to give therapeutic usefulness by improving the pharmacokinetics in vivo of the object peptide and giving the pharmacokinetics in vivo meeting the treating object, to a chimeric peptide where the pharmacokinetics in vivo is improved and the physiological activity of the object peptide is available, to a pharmaceutical composition containing the chimeric peptide and to a process for producing the chimeric peptide.BACKGROUND ART[0002]Even when a physiologically peptide which is able to be applied as a drug is present, some of the peptide has a short half-life in plasma and, in its application for therapeutic purpose, it is necessary to attempt the achievement by means of the continuous administration by intravenous or subcutaneous means or by administration of a DDS preparation of a sustained release type. Therefore, much time and cost for a long period of time are necessary for actual application.[0003]For ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/08C07K7/06C07K7/08C07K14/00C07K14/435A61K38/10A61K38/16A61P9/00A61P19/02A61P3/10
CPCC07K14/00C07K14/58A61K47/62C07K16/26C07K2319/31C07K14/63A61P13/12A61P19/02A61P43/00A61P7/10A61P9/00A61P9/10A61P9/12A61P3/10C07K7/08A61K38/00
Inventor WAKABAYASHI, NAOMISEIJI, SATO
Owner DAIICHI SANKYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap